Please login to the form below

Not currently logged in
Email:
Password:

pegpleranib

This page shows the latest pegpleranib news and features for those working in and with pharma, biotech and healthcare.

Novartis buys two firms in pre-Christmas shopping spree

Novartis buys two firms in pre-Christmas shopping spree

Those only gathered pace after a late-stage setback for age-related macular degeneration (AMD) therapy Fovista (pegpleranib), which was licensed by the company in 2014 in a deal valued at

Latest news

  • Novartis' AMD drug pegpleranib fails phase III programme Novartis' AMD drug pegpleranib fails phase III programme

    Novartis' AMD drug pegpleranib fails phase III programme. Plans for Lucentis-boosting duel-therapy stumble as trial data show no additional benefit. ... Novartis' hopes of positioning pegpleranib as a duo alongside its big-selling age-related macular

  • Novartis says Cosentyx is 'outpacing competitors' Novartis says Cosentyx is 'outpacing competitors'

    These include RLX030 (serelaxin) for acute heart failure, Fovista (pegpleranib) and RTH258 (brolucizumab) for neovascular age-related macular degeneration (AMD), and novel migraine prevention drug AMG334.

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics